Abcam, ab320632, Anti-USP31 + USP43 antibody [EPR26029-42]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal USP43 antibody. Suitable for WB and reacts with Transfected cell lysate - Human, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR26029-42,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody cross-reacts with overexpressed human USP31 (Q70CQ4) by WB.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
USP43 and USP31 are deubiquitinating enzymes that play critical roles in the regulation of protein ubiquitination. These proteins remove ubiquitin molecules from specific substrates controlling their degradation and function. USP43 also known as Ubiquitin-Specific Protease 43 weighs approximately 92 kDa and is mainly expressed in tissues such as the brain and skeletal muscle. USP31 or Ubiquitin-Specific Protease 31 has a mass of around 90 kDa and is found in various tissues including the heart and liver. Both enzymes contribute to maintaining protein homeostasis by modulating the ubiquitin-proteasome system.
Biological function summary
The deubiquitination activity of USP43 and USP31 influences cellular processes like cell cycle progression DNA repair and signal transduction. These enzymes are part of larger multi-protein complexes that facilitate their action on specific substrates. The involvement of USP31 in cell signaling pathways can impact transcriptional regulation while USP43 can influence processes related to neuronal development and function. Their activity ensures precise cellular responses to internal and external cues maintaining overall cellular integrity.
Pathways
Both USP43 and USP31 integrate into important cellular mechanisms such as the NF-kB signaling pathway and the Wnt signaling pathway. In the NF-kB pathway USP31 interacts with proteins like TRAF proteins which are key to regulating inflammation and immune response. USP43 within the Wnt pathway may modulate the stability of beta-catenin influencing cell fate decisions during development. The activity of these proteins highlights their important roles in signal transduction and maintaining cellular equilibrium.
Alterations in the function or expression of USP43 and USP31 can associate with conditions like cancer and neurodegenerative diseases. For instance dysregulation of USP31 could contribute to the malignant transformation in various cancers potentially through its interactions with NF-kB signaling partners like IKK. Similarly altered function of USP43 may link to neurodegenerative disorders due to its role in maintaining neuronal health. Understanding these relationships allows for potential therapeutic targeting of these proteins in disease treatment strategies.